Anniina Snellman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/570044/publications.pdf

Version: 2024-02-01

31	1,582	394421 19	434195 31
papers	citations	h-index	g-index

31	31	31	1992
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	7.6	20
2	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease â€“ Study Protocol and Baseline Characteristics. Frontiers in Neurology, 2022, 13, 826423.	2.4	7
3	CSF biomarkers and plasma pâ€tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.8	22
4	Time course of phosphorylated-tau181 in blood across the Alzheimerâ€™s disease spectrum. Brain, 2021, 144, 325-339.	7.6	124
5	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	7.9	186
6	Effects of preâ€analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12168.	2.4	52
7	Association between polygenic risk score of Alzheimerâ€™s disease and plasma phosphorylated tau in individuals from the Alzheimerâ€™s Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	6.2	35
8	Plasma p-tau231: a new biomarker for incipient Alzheimerâ€™s disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
9	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 69.	6.2	34
10	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	3.3	15
11	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
12	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
13	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.1	50
14	(S)-[18F]THK5117 brain uptake is associated with AÎ² plaques and MAO-B enzyme in a mouse model of Alzheimer's disease. Neuropharmacology, 2021, 196, 108676.	4.1	7
15	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics, 2021, 11, 6644-6667.	10.0	42
16	Pâ€tau235: a novel biomarker for staging preclinical Alzheimerâ€™s disease. EMBO Molecular Medicine, 2021, 13, e15098.	6.9	30
17	Effect of genotype and age on cerebral [18F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 5700.	3.3	8
18	Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 509-515.	5.0	40

#	Article	IF	Citations
19	Chemical exchange saturation transfer MRI shows low cerebral 2-deoxy-D-glucose uptake in a model of Alzheimerâ€™s Disease. Scientific Reports, 2018, 8, 9576.	3.3	33
20	[18F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 69, 199-208.	3.1	23
21	Applicability of [11 C]PIB micro-PET imaging for inÂvivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiology of Aging, 2017, 57, 84-94.	3.1	17
22	Ex Vivo Tracing of NMDA and GABA-A Receptors in Rat Brain After Traumatic Brain Injury Using ¹⁸F-GE-179 and ¹⁸F-GE-194 Autoradiography. Journal of Nuclear Medicine, 2016, 57, 1442-1447.	5.0	18
23	18 F-labeling syntheses and preclinical evaluation of functionalized nanoliposomes for Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2016, 88, 257-266.	4.0	6
24	Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. Brain Research, 2016, 1652, 97-102.	2.2	2
25	Multifunctional Liposomes Reduce Brain Î²-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models. Journal of Neuroscience, 2014, 34, 14022-14031.	3.6	141
26	6-[18F]Fluoro-l-DOPA Uptake in the Rat Pancreas is Dependent on the Tracer Metabolism. Molecular Imaging and Biology, 2014, 16, 403-411.	2.6	2
27	Synthesis and evaluation of a 18F-curcumin derivate for Î²-amyloid plaque imaging. Bioorganic and Medicinal Chemistry, 2014, 22, 2753-2762.	3.0	32
28	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol. EJNMMI Research, 2014, 4, 37.	2.5	22
29	¹⁹F/¹⁸F exchange synthesis for a novel [¹⁸F]S1P₃â€radiopharmaceutical. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 385-391.	1.0	6
30	Longitudinal Amyloid Imaging in Mouse Brain with ¹¹C-PIB: Comparison of APP23, Tg2576, and APP_{swe}-PS1_{dE9} Mouse Models of Alzheimer Disease. Journal of Nuclear Medicine, 2013, 54, 1434-1441.	5.0	71
31	Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1784-1795.	6.4	52